What our patients want and need to know about generalized anxiety disorder?

被引:1
作者
Allgulander, Christer
机构
关键词
D O I
10.1590/S1516-44462006005000023
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Persons with generalized anxiety disorder often do not seek treatment, and if they do, it is more often for the somatic symptoms (muscle tension, insomnia) or for a secondary depression than because of the cardinal feature of generalized anxiety disorder: worry. The worry aspect becomes apparent when the patient is proposed to try anxiolytic medication. The physician will then need to be prepared to answer many questions regarding the potential hazards and benefits of such medication. These patients tend to have a sceptical attitude, having informed themselves on websites that display claims that are based on anything from evidence-based scientific guidelines to distorted, erroneous and unfounded allegations. Which are the frequent questions that worried patients pose to the physician before accepting anxiolytic pharmacotherapy? Having seen anxious patients in my practice during 25 years, and having conducted several clinical trials of anxiolytics/have put together evidence-based answers in plain language to these questions in this paper.
引用
收藏
页码:172 / 176
页数:5
相关论文
共 31 条
[1]   WCA-recommendations for the long-term treatment of generalized anxiety disorder [J].
Allgulander, C ;
Bandelow, B ;
Hollander, E ;
Montgomery, SA ;
Nutt, DJ ;
Okasha, A ;
Pollack, MH ;
Stein, DJ ;
Swinson, RP .
CNS SPECTRUMS, 2003, 8 (08) :53-61
[2]  
Allgulander C, 1998, PSYCHOPHARMACOL BULL, V34, P165
[3]   Prevention of relapse in generalized anxiety disorder by escitalopram treatment [J].
Allgulander, Christer ;
Florea, Ioana ;
Huusom, Anna K. Trap .
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2006, 9 (05) :495-505
[4]   Prevalence of ICD-10 mental disorders in a catchment area in the city of Sao Paulo, Brazil [J].
Andrade, L ;
Walters, EE ;
Gentil, V ;
Laurenti, R .
SOCIAL PSYCHIATRY AND PSYCHIATRIC EPIDEMIOLOGY, 2002, 37 (07) :316-325
[5]   Evidence-based pharmacotherapy of generalized anxiety disorder [J].
Baldwin, DS ;
Polkinghorn, C .
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2005, 8 (02) :293-302
[6]   Specifying race-ethnic differences in risk for psychiatric disorder in a USA national sample [J].
Breslau, J ;
Aguilar-Gaxiola, S ;
Kendler, KS ;
Su, M ;
Williams, D ;
Kessler, RC .
PSYCHOLOGICAL MEDICINE, 2006, 36 (01) :57-68
[7]   Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: A 12-year prospective study [J].
Bruce, SE ;
Yonkers, KA ;
Otto, MW ;
Eisen, JL ;
Weisberg, RB ;
Pagano, M ;
Shea, MT ;
Keller, MB .
AMERICAN JOURNAL OF PSYCHIATRY, 2005, 162 (06) :1179-1187
[8]   Assessment of beliefs about psychotropic medication and psychotherapy: development of a measure for patients with anxiety disorders [J].
Bystritsky, A ;
Wagner, AW ;
Russo, JE ;
Stein, MB ;
Sherbourne, CD ;
Craske, MG ;
Roy-Byrne, PP .
GENERAL HOSPITAL PSYCHIATRY, 2005, 27 (05) :313-318
[9]   Influence of life stress on depression: Moderation by a polymorphism in the 5-HTT gene [J].
Caspi, A ;
Sugden, K ;
Moffitt, TE ;
Taylor, A ;
Craig, IW ;
Harrington, H ;
McClay, J ;
Mill, J ;
Martin, J ;
Braithwaite, A ;
Poulton, R .
SCIENCE, 2003, 301 (5631) :386-389
[10]   Pregabalin: In the treatment of generalised anxiety disorder [J].
Frampton J.E. ;
Foster R.H. .
CNS Drugs, 2006, 20 (8) :685-693